FDA Stops Short Of Opiates Recall After Product Mix-Up At Novartis Plant
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency issued a public health advisory warning pharmacists and patients to inspect bottles of opiate products made at the plant, including Endo’s Percocet and Percodan, for improper pills; an FDA official says the risk-benefit analysis is different for Novartis OTC products, which were voluntarily recalled.